UCHL1 loss alters the cell cycle in metastatic pancreatic neuroendocrine tumors
نویسندگان
چکیده
منابع مشابه
Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors are usually indolent (slow-growing) by nature and develop over the course of many years. Pancreatic neuroendocrine tumors are usually more indolent, with better prognosis than adenocarcinoma of the pancreas (Carriaga & Henson, 1995). However, aggressive, fast growing pancreatic neuroendocrine tumors exist and different types of pancreatic neuroendocrine tumors e...
متن کاملBiomarkers in pancreatic neuroendocrine tumors.
The aim of biomarkers is to identify patients most likely to benefit from a therapeutic strategy. Pancreatic neuroendocrine tumors are rare neoplasms that arise in the endocrine tissues of the pancreas. Pancreatic neuroendocrine tumors represent 3% of primary pancreatic neoplasms and their incidence has risen. The SMAD4 gene is located on chromosome 18q and someday the SMAD4 gene status may be ...
متن کاملDiagnosis of Pancreatic Neuroendocrine Tumors
Pancreatic neuroendocrine tumors (PNETs) are relatively rare; however, the incidence has increased over the last few decades. They are classified as functional or non-functional tumors according to the presence of associated clinical symptoms. The majority are non-functional tumors. For classification and staging, the World Health Organization 2010 classification system is the most commonly acc...
متن کاملMetastatic neuroendocrine tumors of the parotid gland.
OBJECTIVES To present 2 cases of neuroendocrine tumors of the parotid gland and to review the clinical presentation, histopathologic, and immunohistochemical findings and treatment of these rare tumors. STUDY DESIGN Case series. METHODS This study reviews 2 patients who both presented with firm masses in the parotid gland diagnosed as neuroendocrine carcinoma by histopathologic and immunohi...
متن کاملLanreotide in metastatic enteropancreatic neuroendocrine tumors.
BACKGROUND Somatostatin analogues are commonly used to treat symptoms associated with hormone hypersecretion in neuroendocrine tumors; however, data on their antitumor effects are limited. METHODS We conducted a randomized, double-blind, placebo-controlled, multinational study of the somatostatin analogue lanreotide in patients with advanced, well-differentiated or moderately differentiated, ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Endocrine-Related Cancer
سال: 2019
ISSN: 1351-0088,1479-6821
DOI: 10.1530/erc-18-0507